Navigation Links
Lilly to Streamline Indianapolis Manufacturing and Engineering Operations
Date:4/16/2008

Company taking steps to transform its business; employment to be reduced by

up to 500

INDIANAPOLIS, April 16 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced a streamlining of a portion of its manufacturing operations in Indianapolis. These actions, which affect sites that manufacture active pharmaceutical ingredients for the insulin products Humalog(R) and Humulin(R) as well as for the osteoporosis medicine Forteo(R), will align manufacturing capacity and engineering support services with the needs of the business.

Lilly is offering a voluntary exit program to employees in selected areas, with enhanced financial incentives for those who leave the company. In total, the voluntary program is expected to reduce Lilly's Indianapolis employment by up to 500 people, predominantly in manufacturing but with a small portion in selected areas of research and development.

"For several years we have focused on strategic efforts to lower costs, increase flexibility, and improve productivity across the business," said John C. Lechleiter, Ph.D., Lilly president and chief executive officer. "This strategy calls for reducing investments in some areas while increasing investments in others, and the streamlining decisions announced today are an example of this."

Added Lechleiter, "We are constantly assessing our manufacturing capacity and taking the necessary steps to align it with the demands of the business. In particular, we must align our production capacity with anticipated customer demands over a time period in which some products will lose patent protection while other new products are launched."

"While these are necessary decisions, they are difficult because they affect our people," said Lechleiter. "From a peak employment level in mid-2004, we have reduced our global headcount by twelve percent, or about 5,500 people. These reductions have occurred primarily through attrition. But at times, including this one, we have had to take additional measures as we have restructured our operations. As we fulfill our responsibilities to all of our stakeholders, we are intent on upholding the Lilly values by treating all employees - particularly those directly affected by these changes - fairly and with the utmost respect."

As a result of these actions the company will be taking an accounting charge in the second quarter of 2008. The amount of that charge has not yet been determined, as it will depend upon the numbers of employees that choose to take the exit package.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.

This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. Management cannot predict with certainty the number of employees that will elect to participate in the voluntary exit program or whether this program will meet its business objectives. For additional information about the factors that affect the company's business, please see the company's latest Form 10-K filed February 2008. The company undertakes no duty to update forward-looking statements.

Forteo(R) (teriparatide of recombinant DNA origin injection, Lilly)

Humalog(R) (insulin lispro injection of recombinant DNA origin, Lilly)

Humulin(R) (human insulin of recombinant DNA origin, Lilly)

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lilly Adjusts Time of Conference Call for First Quarter 2008 Financial Results Announcement
2. Lilly Sets Date and Conference Call for First Quarter 2008 Financial Results Announcement
3. State of Alaska and Eli Lilly and Company Reach Agreement to Settle Zyprexa Lawsuit
4. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
5. Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
6. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
7. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
8. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
9. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
10. Michael L. Eskew Elected to Lilly Board of Directors
11. Lilly Caps Successful Year with Strong Fourth-Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 31, 2016 , ... Splashtop Inc., the worldwide leader in high performance ... the leading provider of secure mobile remote access solution for Japan enterprises. ... remote access solution. Splashtop for CACHATTO will be available as an integrated ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices ... But this approach has proven transformative, both for people who hear voices and for ... is used around the world, but it still lags in the United States. , ...
(Date:5/31/2016)... ... May 31, 2016 , ... When ... he knew it was something that contractors should have at their disposal on ... gets,” says Butch, CertainTeed’s Director of Contractor Programs. , As a result, ...
(Date:5/31/2016)... Severna Park, Maryland (PRWEB) , ... May 31, ... ... the ability to attribute calls back to particular advertising campaigns, to monitor the ... teams so that they can maximize conversions and revenue. The software allows customers ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only drive service to ... a whole. On June 2, Northbound CEO Mike Neatherton and COO Paul Alexander will ... the opening plenary on “Leadership: The Journey to Authenticity” with Onsite Workshops CEO Miles ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharmaceutical company focused on late-stage drug development, ... Dexcel Pharma of pivotal batches required for ... Drug Administration (FDA). This follows Kitov,s announcement ... III trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
Breaking Medicine Technology: